Cargando…

TB and HIV Therapeutics: Pharmacology Research Priorities

An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co-infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care. To ensure that combinations of anti-tub...

Descripción completa

Detalles Bibliográficos
Autores principales: Dooley, Kelly E., Kim, Peter S., Williams, Sharon D., Hafner, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398575/
https://www.ncbi.nlm.nih.gov/pubmed/22829999
http://dx.doi.org/10.1155/2012/874083
_version_ 1782238298736951296
author Dooley, Kelly E.
Kim, Peter S.
Williams, Sharon D.
Hafner, Richard
author_facet Dooley, Kelly E.
Kim, Peter S.
Williams, Sharon D.
Hafner, Richard
author_sort Dooley, Kelly E.
collection PubMed
description An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co-infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care. To ensure that combinations of anti-tuberculosis drugs and antiretrovirals are safe and are tested at doses most likely to be effective, selected pharmacokinetic studies based on knowledge of their metabolic pathways and their capacity to induce or inhibit metabolizing enzymes of companion drugs must be conducted. Drug interaction studies should be followed up by evaluations in larger populations to evaluate safety and pharmacodynamics more fully. Involving patients with HIV in trials of TB drugs early in development enhances the knowledge gained from the trials and will ensure that promising new tuberculosis treatments are available to patients with HIV as early as possible. In this review, we summarize current and planned pharmacokinetic and drug interaction studies involving investigational and licensed tuberculosis drugs and antiretrovirals and suggest priorities for tuberculosis-HIV pharmacokinetic, pharmacodynamic, and drug-drug interaction studies for the future. Priority studies for children and pregnant women with HIV and tuberculosis co-infection are briefly discussed.
format Online
Article
Text
id pubmed-3398575
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33985752012-07-24 TB and HIV Therapeutics: Pharmacology Research Priorities Dooley, Kelly E. Kim, Peter S. Williams, Sharon D. Hafner, Richard AIDS Res Treat Review Article An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co-infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care. To ensure that combinations of anti-tuberculosis drugs and antiretrovirals are safe and are tested at doses most likely to be effective, selected pharmacokinetic studies based on knowledge of their metabolic pathways and their capacity to induce or inhibit metabolizing enzymes of companion drugs must be conducted. Drug interaction studies should be followed up by evaluations in larger populations to evaluate safety and pharmacodynamics more fully. Involving patients with HIV in trials of TB drugs early in development enhances the knowledge gained from the trials and will ensure that promising new tuberculosis treatments are available to patients with HIV as early as possible. In this review, we summarize current and planned pharmacokinetic and drug interaction studies involving investigational and licensed tuberculosis drugs and antiretrovirals and suggest priorities for tuberculosis-HIV pharmacokinetic, pharmacodynamic, and drug-drug interaction studies for the future. Priority studies for children and pregnant women with HIV and tuberculosis co-infection are briefly discussed. Hindawi Publishing Corporation 2012 2012-07-05 /pmc/articles/PMC3398575/ /pubmed/22829999 http://dx.doi.org/10.1155/2012/874083 Text en Copyright © 2012 Kelly E. Dooley et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dooley, Kelly E.
Kim, Peter S.
Williams, Sharon D.
Hafner, Richard
TB and HIV Therapeutics: Pharmacology Research Priorities
title TB and HIV Therapeutics: Pharmacology Research Priorities
title_full TB and HIV Therapeutics: Pharmacology Research Priorities
title_fullStr TB and HIV Therapeutics: Pharmacology Research Priorities
title_full_unstemmed TB and HIV Therapeutics: Pharmacology Research Priorities
title_short TB and HIV Therapeutics: Pharmacology Research Priorities
title_sort tb and hiv therapeutics: pharmacology research priorities
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398575/
https://www.ncbi.nlm.nih.gov/pubmed/22829999
http://dx.doi.org/10.1155/2012/874083
work_keys_str_mv AT dooleykellye tbandhivtherapeuticspharmacologyresearchpriorities
AT kimpeters tbandhivtherapeuticspharmacologyresearchpriorities
AT williamssharond tbandhivtherapeuticspharmacologyresearchpriorities
AT hafnerrichard tbandhivtherapeuticspharmacologyresearchpriorities